Double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate efficacy and safety of 4 and 8 million units Betaferon(R)/Betaseron(R) (interferon beta-1b) given subcutaneously every other day over 24 weeks in patients with chronic viral cardiomyopathy

Trial Profile

Double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate efficacy and safety of 4 and 8 million units Betaferon(R)/Betaseron(R) (interferon beta-1b) given subcutaneously every other day over 24 weeks in patients with chronic viral cardiomyopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2008

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Adenovirus infections; Cardiomyopathies; Enterovirus infections; Parvovirus infections
  • Focus Therapeutic Use
  • Acronyms BICC
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 11 Nov 2008 Secondary endpoint 'Exercise testing' has not been met, according to an American Heart Association media release.
    • 11 Nov 2008 Secondary endpoint 'Left ventricular ejection fraction' has not been met, according to an American Heart Association media release.
    • 11 Nov 2008 Secondary endpoint 'Quality of life' has not been met, according to an American Heart Association media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top